drugset / Trial / NCT06949137
Intravenous Infusion of Human Mesenchymal Stem Cells (HMM910 ) in Postmenopausal Women With Osteoporosis at High Risk of Fracture
Phase 1
Active not recruiting
9 enrolled
HELP Therapeutics Co., Ltd.
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
The primary objective of this study is to evaluate the safety and tolerability of human umbilical cord-derived mesenchymal stem cells for injection (HMM910 ) in postmenopausal women with osteoporosis who are at high risk of fracture.
Timeline
- Start
- 2025-06-20
- Primary completion
- 2026-03-06
- Completion
- 2026-09-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HMM910 | Cell therapy | 6e+07 cells | Intravenous |
| Subject | HMM910 | Cell therapy | 1.2e+08 cells | Intravenous |
| Subject | HMM910 | Cell therapy | 2.4e+08 cells | Intravenous |